Tissue-specific effects on uptake of 99mTc-sestamibi by breast lesions: a targeted analysis of false scintigraphic diagnoses.

The limited spatial resolution of gamma-cameras is commonly considered the main reason for the low sensitivity of scintimammography in the detection of small carcinomas. The present study assessed whether uptake of (99m)Tc-sestambi is affected by certain tissue-specific parameters besides the size of the tumor. METHODS: Surgical specimens from 75 patients (30 benign lesions, 8 of which had shown false-positive scintigraphic findings, and 45 carcinomas, 8 of which had shown false-negative scintigraphic findings) were subjected to a distinct histopathologic/immunohistochemical reevaluation. Tissue-specific parameters (lesion size, cellular density, vascularity, signs of inflammation, proliferative activity, multidrug resistance expression, and receptor status) were visually scored and correlated with the sestamibi uptake on scintimammograms. RESULTS: A clear relationship was found between sestamibi uptake and tumor size. As previously assumed, a lesion size of less than 1 cm in diameter was found to be one reason for false-negative scintigraphic diagnoses. In addition, a low cell count, low vascularity, and absence of inflammation in carcinomas had a negative effect on uptake of the radiopharmaceutical. The decisive factor for increased tracer uptake by benign lesions was the presence of inflammatory changes. No correlation could be found between sestamibi uptake and proliferative cellular activity, multidrug resistance expression, or the receptor status of the tumor. CONCLUSION: Because all mentioned findings were statistically significant only in part, it is to be supposed that uptake of (99m)Tc-sestambi by breast lesions is determined by various tissue parameters in interaction.     

Direct labelling of octreotide with 99mTc: effect of different concentration of reducing agents and amount of sodium pertechnetate on radiolabelling efficiency.

Octreotide, a synthetic analog of natural hormone somatostatin, was labelled with 99mTc. Labelling was accomplished by reduction of the cysteine bridge, which provided sulfhydryl groups for chelating with 99mTc. Sodium ascorbate and sodium dithionite in different concentrations were used as reducing agents. Different amounts of sodium pertechnetate were used for labelling of peptide. When the mass ratio of peptide and sodium ascorbate was 1:100 and the final concentration of dithionite in the labelling vial was 0.2-0.4 microg/microl with 0.18-1.48 GBq sodium pertechnetate more than 80% radiolabelling efficiency was confirmed by RP-HPLC, ITLC-SG and C18 Cartridge analysis. The stability of the 99mTc-peptide bond was evaluated by human serum challenge and that showed the stability was 90% after 4h.     

Evaluation of destructive effects of exposure to cisplatin during developmental stage: no profound evidence for sex differences in impaired motor and memory performance

We have elucidated the alteration in hippocampal and cerebellum function following chronic cisplatin treatment in male and female rats. Hippocampus and cerebellum related behavioral dysfunction in cisplatin-treated [intraperitoneally, 5 mg/(kg/week) for 5 weeks from 23-day-old] rats were analyzed using explorative, motor function, learning, and memory tasks (grasping, rotarod, open field, and Morris water maze tests). Exposure to cisplatin impaired the motor coordination in male and female rats. Exposure to cisplatin was reflected by a decrease in grasping time compared to vehicle-treated controls (saline) only in male rat while there were not any differences in female rats. When the rearing frequency, total distance moved and velocity of their recorded in open fieldtest, both males and females were dramatically affected by exposure to cisplatin. Compared to the saline, male and female rats trained 5 weeks after cisplatin injection showed significant memory deficits in the Morris water maze test. However, hippocampal and cerebellum functions of male and female rats were profoundly affected by exposure to cisplatin while no sex differences in the most variable were evident.